Innovating Works

FLAVIVACCINE

Financiado
Development and characterization of a pan-flavivirus vaccine candidate
Dengue, yellow fever, Zika, and West Nile viruses are mosquito-borne flaviviruses and global public health burdens that infect half a billion people annually, causing 250,000 deaths, and threaten nearly the entire human population... Dengue, yellow fever, Zika, and West Nile viruses are mosquito-borne flaviviruses and global public health burdens that infect half a billion people annually, causing 250,000 deaths, and threaten nearly the entire human population. In a context of human-driven global changes, these threats will intensify with larger and more frequent epidemics, potentially leading to pandemics, will expand with geographic spreading of the mosquito vectors, and will multiply with the likely emergence of yet-unknown flaviviruses. Improving pandemic preparedness and response to these emerging and re-emerging diseases is a top priority both for the EU and WHO. However, there are no effective interventions against all flaviviruses and current vaccines targeting flaviviral proteins have severe safety issues. FLAVIVACCINE’s high-impact/low-risk/disruptive ambition is to develop a novel, broad-spectrum, mosquito saliva-targeted vaccine candidate that protects against multiple different flaviviruses and is ready for clinical evaluation by building upon an experimentally-validated proof-of-concept. FLAVIVACCINE will define the immunogenicity of the pan-flavivirus target, develop and characterize a vaccine candidate against multiple flaviviruses, and prepare it for clinical evaluation. To reach these goals, FLAVIVACCINE creates a unique interdisciplinary environment of ten public and private institutions, including Universities, Research Institutions and a Vaccine Developer, from seven countries to cover all the required scientific expertise and knowledge in cell biology, virology, immunology and vaccinology. The pan-flavivirus vaccine candidate that will be validated against dengue, yellow fever, Zika and West Nile diseases in several preclinical models, together with the knowledge and networks resulting from FLAVIVACCINE, will have short- and long-term impact on the EU ability to combat epidemic and pandemic viral threats, and protect communities and citizens in the EU and around the world. ver más
31/12/2027
IRD
8M€
Duración del proyecto: 48 meses Fecha Inicio: 2023-12-13
Fecha Fin: 2027-12-31

Línea de financiación: concedida

El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-12-13
Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:
HORIZON-HLTH-2023-DISEASE-03-18: Pandemic preparedness and response: Immunogenicity of viral proteins of viruses with epidemic and pandemic potential
Cerrada hace 1 año
Presupuesto El presupuesto total del proyecto asciende a 8M€
Líder del proyecto
INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico TRL 4-5